Erythropoietin-induced, antibody-mediated pure red cell aplasia

Jérôme Rossert*, Brad Maroni, Pedro Aljama, Nicole Casadevall, Max Cooper, Robert Delage, Kai Uwe Eckardt, Angel Martin Luis De Francisco, Walter Hörl, Wolfgang Jelkmann, David Johnson, Francesco Locatelli, Iain Macdougall, Allen R. Nissenson, Carol Pollock, Huub Schellekens, Robin Thorpe, Edwin Toffelmire

*Corresponding author for this work
22 Citations (Scopus)


Pure red cell aplasia (PRCA) is a rare haematological condition that is characterized by severe aregenerative anaemia due to an almost complete cessation of red blood cell production. While antibody-mediated PRCA was extremely rare before 1998, the incidence of this disorder increased sharply after 1998 in patients receiving subcutaneous epoetin alfa produced by Ortho-Biotech and marketed outside the USA. The diagnosis of antibody-mediated PRCA relies mostly on the results of bone marrow biopsy or aspirate, which shows an absence of erythroid precursors and/or red cell maturation arrest while counts of white cell and platelet precursors are normal, and on the identification of circulating anti-erythropoietin antibodies. Retrospective analysis of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients.

Original languageEnglish
JournalEuropean Journal of Clinical Investigation, Supplement
Issue number3
Pages (from-to)95-99
Number of pages5
Publication statusPublished - 12.2005

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)


Dive into the research topics of 'Erythropoietin-induced, antibody-mediated pure red cell aplasia'. Together they form a unique fingerprint.

Cite this